Cowen Downgrades Merrimack Pharmaceuticals (MACK) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Merrimack Pharma (MACK) Misses Q2 EPS by 7c
August 4, 2016 4:13 PM EDTMerrimack Pharma (NASDAQ: MACK) reported Q2 EPS of ($0.40), $0.07 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $33.7 million versus the consensus estimate of $30.97 million.
Financial Outlook
In an effort to provide... More
